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We read with great interest the recently published study by Williams et al [1]. The authors sought to determine the 
relationship between postoperative clopidogrel and clinical and angiographic outcomes following coronary artery 
bypass grafting (CABG)[1]. Although clopidogrel is now recommended as postoperative antiplatelet therapy in 
patients with recent acute coronary syndromes, some other circumstances such as off-pump CABG, performed 
endarterectomy, and extensive severe coronary artery disease with small target vessels, warrant the use of both 
clopidogrel and aspirin following surgical revascularization [2]. In present study by Williams et al[1], postoperative 
antiplatelet therapy was left to physician discretion, thus creating patient selection bias since above mentioned 
circumstances requiring dual antiplatelet therapy (dAPT) could influence angiographic as well as clinical outcomes. 
Aortocoronary vein graft disease is composed of three distinct but interrelated pathological processes: thrombosis, 
intimal hyperplasia, and atherosclerosis[3]. Early thrombosis is a major cause of vein graft attrition during the first 
month after CABG[3]. Since the present study assessed clinical outcome [1] it would be interesting if authors 
included in analysis patients who died prior to 30 days postoperatively. It would be interesting to elucidate how 
many patients of those who died prior to 30 days postoperatively were on dAPT vs. mono antiplatelet therapy early 
after CABG?  
In our opinion, the lack of data concerning objective quantification of the antiplatelet effect of aspirin and 
clopidogrel constitutes a major drawback of the study. Expected inhibition of platelet function is not always achieved 
after aspirin and/or clopidogrel administration. The frequency of low responsiveness for the 2 drugs has been 
reported to range from 1% to 45% [4, 5] and such a phenomenon could certainly explain in some degree ischemic 
events after CABG. When assessing relationship between postoperative dAPT and both clinical and angiographic 
outcomes following CABG, the role of aspirin should inextricably be included into considerations. Within dAPT the 
possible impact of each antiplatelet agent (aspirin and clopidogrel) on clinical and angiographic outcomes should 
separately be assessed by drug specific platelet function tests, facilitating individual therapeutic approach for each 
antiplatelet agent postoperatively. Such an approach could distinguish patients with high residual platelet activity, 
thus proclivity to ischemic events, from those with enhanced platelet inhibition, thus proclivity to bleeding events 
(notably, not captured in present trial). In our recent study[5], we analyzed the proportion of patients with aspirin 
resistance, both pre- and postoperatively. Considering all CABG patients, we observed 31/99 (31.3%) patients with 
aspirin resistance preoperatively [5]. Postoperatively, we registered 46/99 (46.5%) CABG patients with aspirin 
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resistance, suggesting platelet hyperactivity[5]. A postoperatively registered increase of 15.2% in the proportion of 
patients with aspirin resistance was found to be significant (p=0.04) as well as higher prevalence of aspirin resistance 
within diabetic subpopulation (58.5% vs 38%, p=0.04). Postoperatively, we observed significant increase in values 
of platelet function tests sensitive to effect of aspirin and clopidogrel[5]. Those findings suggest the fact that decision 
making in postoperative antiplatelet therapy management should be personalized according to drug specific platelet 
function tests with detection of high residual platelet reactivity and subsequent adjustments in treatment modalities. 
Administration of dAPT (dosage and duration adjustment) should be also targeted after subsequent platelet function 
testing. However, this therapeutic approach needs a randomized controlled trial with a large study group to evaluate 
the benefit of such treatment modality. With this aim we are currently conducting a randomized controlled trial[6]. 
Patients in whom postoperative multiple electrode aggregometry documents aspirin resistance will be randomized 
into two groups[6]. The control group will receive 300 mg of aspirin[6]. The dAPT group will receive 75 mg of 
clopidogrel in addition to 300 mg of aspirin[6]. To our best knowledge, this is the only ongoing clinical outcome trial 
that will specifically address the issue of dAPT in patients undergoing CABG who have been found to be aspirin 
resistant in early postoperative phase[6]. Such an approach could shed a light at the possible indication for dAPT in 
CABG patients[6]. Before final recommendations can be made regarding the impact of dAPT administration after 
CABG, randomized controlled trials evaluating clinical outcomes and using drug specific platelet function tests are 
required to address this issue and shift antiplatelet therapy administration management towards personalized 
approach aiming to minimize bleeding and adverse ischemic events. We congratulate the authors on their elegant and 
timely research. 
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